Malabsorption Syndromes and Risk of Age-Related Macular Degeneration: Evidence from Real-World Data

LensesMacular Diseases

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

BMC Ophthalmol

Hengerer FH, Stanzel B, Hoyos-Chacon J, Suarez M, Beckers S, Busatto P, Badalà F

doi: 10.1186/s12886-025-04515-9

Macular Diseases

Associations of cardiovascular-kidney-metabolic syndrome with age-related macular degeneration risk

Am J Ophthalmol

Wu F, Xu K, Zhao Y, Wang W, Yang H, Li Y, Zheng G, Li Z, Xia Y, Liu Y, Wu H, Bai S

doi: 10.1016/j.ajo.2026.01.023

Macular Diseases

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Am J Ophthalmol

Shen M, Berni A, Liu J, Hiya F, Herrera G, El-Mulki OS, Beqiri S, Cheng Y, Kastner J, Trivizki O, Kumar S, Zhang Y, Le VH, O'Brien RC, Nicola MD, Yehoshua Z, Dubovy SR, Wang RK, Gregori G, Rosenfeld PJ

doi: 10.1016/j.ajo.2025.09.006

Macular Diseases

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

J Clin Med

Jeong A, Liang H, Baek SC, Sagong M

doi: 10.3390/jcm14155412

Macular Diseases

Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study

Clin Ophthalmol

Lorenz K, Haritoglou C, Barthelmes D, Sefat AMM, Berk H, Beeke E, Scheffler M, Iwersen M, Müller B, Ziemssen F, members of the PACIFIC study group

doi: 10.2147/OPTH.S512630

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular Diseases

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Ophthalmol Ther

Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D

doi: 10.1007/s40123-025-01140-z

Related content

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

Associations of cardiovascular-kidney-metabolic syndrome with age-related macular degeneration risk

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study